Kratom Scheduling: Feds Draw a Line at 7-OH Opioids

The kratom scheduling fight just took a sharp turn: federal health officials now want a clear line between leaf powder from the gas station shelf and the lab-boosted opioid products that have exploded in vape shops and convenience stores. If you or your friends have ever grabbed a "wellness" shot at the counter, this one is about you.

On Friday, the Department of Health and Human Services sent the Drug Enforcement Administration a new recommendation on how to schedule two compounds tied to kratom products, according to an HHS press release. They are 7-hydroxymitragynine, usually shortened to 7-OH, and mitragynine pseudoindoxyl, or MGPI. The Justice Department said DEA issued fresh notices of intent to match.

What officials actually proposed

The idea is a threshold, not a blanket ban on the plant. Under the HHS recommendation, either compound, or the two combined, would land in Schedule I when a solid product holds more than one milligram per gram, or a liquid holds more than one milligram per milliliter. A second test also applies: if the ratio of mitragynine to the boosted compounds is under one hundred to one, the product is covered.

That ratio test matters because natural kratom leaf is mostly mitragynine, with only trace 7-OH. HHS says the goal is to catch products "intentionally enhanced or concentrated" while leaving botanical kratom alone. Health Secretary Robert F. Kennedy Jr. put it bluntly in the release: "We are drawing a clear line between natural kratom and dangerous, enhanced opioid products."

Why 7-OH is the target

The FDA's review, as quoted by HHS, found 7-OH is far stronger than morphine in preclinical studies, roughly two to nine times more potent depending on the study. That is not a typo. The agency also flagged evidence of a meaningful risk of opioid-like dependence and withdrawal from MGPI.

This is the part that gets lost in the memes. Plenty of people think anything sold as kratom is a mild herbal pick-me-up. The compounds at issue here are the concentrated versions, and regulators say they behave like opioids, not like tea.

How we got here

The timeline has been messy. HHS first recommended Schedule I treatment for 7-OH above a set threshold in July of last year. This past July, DEA announced it planned to temporarily schedule 7-OH, and HHS asked the public to weigh in on the threshold.

DEA then temporarily placed MGPI and two synthetic 7-OH relatives, called MGM-15 and MGM-16, in Schedule I. According to The Well News, those controls stay in effect during the new thirty-day notice period and until a replacement order is issued. DEA has not yet issued a temporary scheduling order for 7-OH itself.

Questions then piled up about whether scheduling MGPI could accidentally sweep in natural kratom that carries trace amounts. The new threshold is HHS's answer to that worry. Attorney General Todd Blanche said in the Justice Department announcement that "dangerous and addictive opioids do not belong behind convenience store counters."

Is it banned yet?

Not yet, and this is where people are getting confused online. A notice of intent is a proposal with a waiting period, not the final order. Pain News Network reported that the amended order is expected to take effect in mid November, though advocates stress that the current step is still only a notice.

The Marijuana Herald reported that the notice is scheduled for Federal Register publication next week. It also noted that the new one milligram per gram line works out to about a tenth of a percent by weight, which is looser than the earlier July proposal's lower concentration limit. Some products below that line could still be caught by the ratio test.

Who is cheering and who is not

The American Kratom Association, which represents sellers of traditional leaf products, applauded the targeted approach in a statement. A group called the 7-HOPE Alliance, speaking for 7-OH users, pushed back, saying the thresholds favor certain product categories over others. So the industry is split, and the details of the final rule will decide who wins.

For shoppers, the practical takeaway is simple. Check labels for 7-OH, and be skeptical of anything marketed as extra strong, extracted, or "pure." If a product claims a punch far beyond plain leaf, that is exactly the profile regulators are aiming at.

What to watch next

Keep an eye on the Federal Register notice and the thirty-day comment window that follows. Dispensing shops, vape retailers and gas stations will have to decide fast what stays on shelves. States may also move on their own, as several already have.

If you want more on the health side of this story, browse our health coverage for the latest. The bigger question is whether kratom scheduling can really separate a leaf from a lab product in the real world, or whether enforcement will blur that line again.